Penn Engineers Create AI to Control Cellular Signals via Peptides

In an ambitious leap forward for peptide drug design, researchers at the University of Pennsylvania and The Chinese University of Hong Kong have unveiled TD3B, an AI-driven framework that not only generates peptide candidates but also predicts their biological effect on target receptors. This breakthrough paper, presented as a Spotlight at the 2026 International Conference on Machine Learning, addresses a longstanding challenge in drug discovery: designing molecules that direct cellular behavior, not just bind targets.

Peptides, short chains of amino acids, form the basis of many existing drugs, such as GLP-1 analogs used in diabetes and weight loss therapies. Traditionally, AI models have separately generated peptide sequences and predicted their binding affinity to targets like G protein-coupled receptors (GPCRs), which mediate a third of all drug actions. However, binding alone provides limited insight; the functional outcome—whether the peptide activates (agonist) or inhibits (antagonist) the receptor—is crucial for therapeutic efficacy.

TD3B integrates three core subsystems to surmount this complexity. At its heart lies the “Direction Oracle,” a machine-learning model that predicts how peptide-receptor interactions translate to functional activation or inhibition. Complementing this is a “gated reward” mechanism that biases generation towards peptides predicted to both bind and achieve the desired effect, providing a sophisticated filtering beyond simple binding affinity. Finally, a “training buffer” leverages top-performing candidates to iteratively refine subsequent peptide designs, making the generative process progressively more targeted.

The predictive power of TD3B was validated through computational structural analyses involving the GLP-1 receptor. Agonist peptides generated by TD3B consistently engaged activation-essential sites on the receptor, while antagonist peptides avoided them, despite the model never being explicitly instructed to target those locations. Parallel tests with the orexin 1 receptor, implicated in sleep and addiction behaviors, showed similarly promising patterns, suggesting broad applicability across GPCR families.

This method ushers in a paradigm shift by integrating directionality into the early stages of peptide drug discovery. Rather than producing a multitude of molecules and subsequently screening their effects, TD3B proactively focuses on generating candidates with therapeutic action in mind. This precision could accelerate the path from computational design to clinical candidates, opening doors to more effective treatments for complex conditions like diabetes, addiction, and cancer.

The team is currently synthesizing TD3B-designed peptides for laboratory testing. If experimental assays confirm the AI’s predictions, the framework could revolutionize how peptide medicines are conceived, moving beyond mere target engagement towards prescriptive modulation of cellular signaling pathways.

Pranam Chatterjee, the study’s senior author, emphasizes the significance of this advance: “Designing molecules that not only find the right target but also control its behavior is the next frontier. TD3B marks a pivotal step in embedding this directionality into computational drug design.”

Supported by the High-throughput Institute for Discovery at Penn and the Hong Kong Research Grants Council, this research highlights the synergy of AI, structural biology, and medicinal chemistry in crafting next-generation therapeutics.